Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

GuruFocus.com11-13

Upfront License Fees and Milestone Payments: Received $50 million from Genentech. Cash Runway: Sufficient to fund operations into the first quarter of 2025. Potential Milestone Payments: Up to $220 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483902376?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Jb3.XgL2362FkeBkwxh3wQ--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/495665872de6cf4730170a0388bbd4fb","is_english":true,"pubTime":"2024-11-13 15:16","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483902376","market":"us","top_or_hot":-1,"title":"Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ...","media":"GuruFocus.com","content":"<div>\n<p>Upfront License Fees and Milestone Payments: Received $50 million from Genentech.\nCash Runway: Sufficient to fund operations into the first quarter of 2025.\nPotential Milestone Payments: Up to $220 ...</p>\n\n<a href=\"https://finance.yahoo.com/news/sangamo-therapeutics-inc-sgmo-q3-071654648.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-13 15:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/sangamo-therapeutics-inc-sgmo-q3-071654648.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Upfront License Fees and Milestone Payments: Received $50 million from Genentech.\nCash Runway: Sufficient to fund operations into the first quarter of 2025.\nPotential Milestone Payments: Up to $220 ...</p>\n\n<a href=\"https://finance.yahoo.com/news/sangamo-therapeutics-inc-sgmo-q3-071654648.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SGMO","symbol_name":"Sangamo Therapeutics Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/sangamo-therapeutics-inc-sgmo-q3-071654648.html","article_id":"2483902376","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Jb3.XgL2362FkeBkwxh3wQ--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/495665872de6cf4730170a0388bbd4fb"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483902376","pubTimestamp":1731482214,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Upfront License Fees and Milestone Payments: Received $50 million from Genentech.Cash Runway: Sufficient to fund operations into the first quarter of 2025.Potential Milestone Payments: Up to $220 million from Pfizer for hemophilia A program.Fabry Disease Program: Achieved alignment with FDA for accelerated approval pathway, reducing approval time by three years.eGFR Slope Data: Statistically significant positive mean annualized eGFR slope observed in Fabry disease patients.Hemophilia A Program: Phase 3 AFFINE trial met primary endpoint with Pfizer, showing statistically significant decrease in annualized bleeding rate.GuruFocus has detected 9 Warning Signs with SGMO.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Sangamo Therapeutics Inc  has transformed from a Phase 1/2 company to a pre-BLA company due to significant regulatory developments in its Fabry disease program.The company has signed a neurology epigenetic regulation and caps","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SGMO":"Sangamo Therapeutics Inc","PFE":"辉瑞"},"translate_title":"Sangamo Therapeutics Inc(SGMO)2024年第三季度收益看涨期权亮点：战略进展和……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SGMO":1,"PFE":0.9},"content_text":"Upfront License Fees and Milestone Payments: Received $50 million from Genentech.\nCash Runway: Sufficient to fund operations into the first quarter of 2025.\nPotential Milestone Payments: Up to $220 million from Pfizer for hemophilia A program.\nFabry Disease Program: Achieved alignment with FDA for accelerated approval pathway, reducing approval time by three years.\neGFR Slope Data: Statistically significant positive mean annualized eGFR slope observed in Fabry disease patients.\nHemophilia A Program: Phase 3 AFFINE trial met primary endpoint with Pfizer, showing statistically significant decrease in annualized bleeding rate.\n\n\nWarning! GuruFocus has detected 9 Warning Signs with SGMO.\n\nRelease Date: November 12, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nSangamo Therapeutics Inc (NASDAQ:SGMO) has transformed from a Phase 1/2 company to a pre-BLA company due to significant regulatory developments in its Fabry disease program.\nThe company has signed a neurology epigenetic regulation and capsid delivery license agreement with Genentech, receiving $50 million in upfront license fees and milestone payments.\nSangamo has submitted its first-ever IND application for a neurology indication, marking a significant milestone in its pipeline development.\nThe Fabry disease program has a clear regulatory pathway to accelerated approval, potentially reducing the time to approval by three years.\nPfizer's Phase 3 AFFINE trial for hemophilia A met its primary endpoint, potentially unlocking up to $220 million in regulatory and commercial milestones for Sangamo.\n\n Negative Points \n\nSangamo's cash runway is only sufficient to fund planned operations into the first quarter of 2025, absent additional funding from partnerships or milestone payments.\nThe company is still in the process of securing partnerships for its Fabry program, which could delay potential revenue streams.\nThere is uncertainty regarding the FDA's requirements for the Fabry program, particularly concerning the need for continued statistical significance at 104 weeks.\nThe commercial success of the hemophilia A program is uncertain, especially in light of BioMarin's challenges with a similar product.\nSangamo's financial stability is heavily reliant on successful BLA submissions and potential partnerships, which are not guaranteed.\n\n Q & A Highlights \nQ: Regarding the FDA comments on the Fabry program, does the FDA want to see statistical significance of the eGFR slope at 52 weeks compared to baseline? And what does the assessment at 104 weeks mean? A: (Alexander Macrae, CEO) The FDA has agreed that the eGFR slope at 52 weeks can serve as the primary basis for accelerated approval. There is no requirement for a confirmatory study. The data at 104 weeks will be used to confirm clinical benefits, and we anticipate presenting the two-year data for full approval in 2026.\nQ: When can we expect the next data update from the Fabry program? A: (Nathalie Dubois-Stringfellow, Chief Development Officer) The Phase 1/2 study has become a registrational study, and we expect to have the top-line data in the second quarter of 2025. The last patient visit will be in April 2025, and data cleaning will follow.\nQ: Can you comment on the FDA's approach to the Fabry program compared to previous requirements for other companies? A: (Alexander Macrae, CEO) The FDA's approach has evolved, particularly under Peter Marks at CBER, who is focused on finding paths forward for rare diseases. Our positive eGFR slope data was compelling enough for the FDA to agree to an accelerated approval pathway without requiring a head-to-head trial or additional studies.\nQ: How confident are you that Pfizer will support the approval and commercial launch of the hemophilia A therapy? A: (Alexander Macrae, CEO) Pfizer is in discussions with regulatory authorities, which suggests their continued enthusiasm for the product. We are pleased with the data they will present at the ASH Annual Meeting.\nQ: Is the FDA requiring any specific data from female Fabry patients or those with cardiac variants for the endpoint revolving around renal function? A: (Alexander Macrae, CEO) The FDA discussions have been about Fabry patients in general, not specifically about gender or cardiac involvement. The data set includes a broad range of patients, and improvements have been observed across various measures, including renal function and patient-reported outcomes.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483902376"}